May 3rd 2024
Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Margin comments in nevi histology reports impact re-excision rates
May 1st 2014Histological reports on atypical or dysplastic nevi that include margin comments appear to have a significant impact on how the clinician will proceed regarding the potential re-excision of lesions, according to a recent literature review.
Molecular techniques explain potential nevoid pathways to melanoma
May 1st 2014Many of the current definitions of skin diseases used in dermatology have changed and morphed over the years, as clinicians learn more and amass volumes of new information regarding many different features, characteristics and associations of dermatologic diseases.
Novel strategies minimize actinic keratoses treatment burdens
May 1st 2014Field therapy in patients with multiple facial actinic keratoses (AKs) is important for preventing the development of new, clinically visible lesions and squamous cell carcinoma. Yet, for a number of reasons, including the need for prolonged topical treatment and poor tolerability, field therapy is widely underused.
Targeted drugs lengthen survival for melanoma patients
April 1st 2014Though a cure for melanoma remains elusive, continued research has borne several promising treatment approaches with more targeted drugs that can help lengthen melanoma patients' survival, buying them time until more effective treatments come to light.
Gene profiling test identifies melanoma tumors likely to metastasize
March 25th 2014In the battle against melanoma, a new test has shown that it can identify primary cutaneous melanomas that are likely to metastasize in patients who had negative sentinel lymph node biopsies (SLNB). Data were presented at the 72nd Annual Meeting of the American Academy of Dermatology.
Clinicians emphasize risk of skin cancer in patients with skin of color
March 25th 2014There is a misconception that people with skin of color are not at risk of skin cancer, and dermatologists are responsible for better educating themselves and their patients about this danger, says an expert who spoke at the 72nd Annual Meeting of the American Academy of Dermatology.
Fungal infections may mimic malignancies
March 1st 2014Common diseases can present in unusual ways, so treatment-resistant fungal infections on the skin should be biopsied, as these infections can mimic or coexist with malignancies, according to research presented at the annual meeting of the Canadian Dermatology Association.
Update: Actinic Keratoses | Guidelines aim to standardize, advance actinic keratoses treatments
March 1st 2014Dermatologists and other medical specialists around the world who treat patients with actinic keratoses (AKs or solar keratoses) will soon be able to refer to new evidence-based (S3) guidelines for management.
Resistance to BRAF inhibitors may be overcome with malaria drug
February 24th 2014Though half of melanoma patients with the BRAF mutation respond positively to treatment with BRAF inhibitors, most develop resistance to the drugs and experience disease progression. A new study suggests a drug used to treat malaria may help to block the pathway that causes this BRAF inhibitor resistance.